Precision treatment for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether choosing a treatment based on specific biomarkers (biological clues) works better than the standard approach for people with advanced esophageal squamous cell carcinoma (a type of esophageal cancer) that has not been treated yet. It aims to improve outcomes by tailoring therapy to each person's cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have advanced esophageal squamous cell carcinoma that has not been treated with any cancer therapy before.
- Your overall health should be generally good (able to care for yourself and up and about).
- You must have at least one tumor that can be measured on a scan.
- You must be willing to use effective birth control during the study and for 6 months after treatment.
- You must not have certain health issues, like severe liver or kidney problems, bleeding disorders, or recent other cancers (unless they were cured early-stage).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests a new combination of drugs (QL1706, nab-paclitaxel, and cisplatin) as a first treatment for advanced or metastatic esophageal squamous cell carcinoma. The goal is to see if this combination is safe and effective in shrinking tumors and helping patients live longer.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
This trial combines a type of immunotherapy (tislelizumab) with chemotherapy and a vitamin A derivative (all-trans retinoic acid) to treat advanced esophageal squamous cell carcinoma. It aims to see if this combination helps shrink or control the cancer better than standard treatments.
Hear when a new Valid MeSH Conditions trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.